Johnson & Johnson and Actelion end discussion about strategic transaction

14-Dec-2016 - Switzerland

Johnson & Johnson confirmed it has ended discussions with Actelion Pharmaceuticals Ltd. regarding a potential transaction. Johnson & Johnson was not able to reach an agreement that it believed would create adequate value for its shareholders.

Actelion has taken note of the announcement by Johnson & Johnson (J&J) and confirms that J&J has withdrawn from the discussions. Actelion is engaged in discussions with another party regarding a possible strategic transaction.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances